余敏华;金明珠;狄文;

• 1:上海交通大学医学院附属仁济医院妇产科上海市妇科肿瘤重点实验室癌基因及相关基因国家重点实验室
• 2:上海交通大学医学院

摘要(Abstract)：

卵巢癌是病死率最高的妇科恶性肿瘤之一,初始治疗后复发率高,5年总生存率低,晚期卵巢癌的治疗是临床工作中的难题。PARP抑制剂极大改善了目前卵巢癌的治疗现状。多项临床试验数据表明,PARP抑制剂不仅在一线维持治疗和铂敏感复发维持阶段显著延长卵巢癌患者无进展生存期,使得维持治疗成为卵巢癌治疗的新模式,同时PARP抑制剂在复发性卵巢癌治疗方面也显示出一定疗效,PARP抑制剂联合治疗可能成为未来卵巢癌的治疗方向。

关键词(KeyWords)： 卵巢癌;PARP抑制剂;BRCA基因突变;维持治疗;铂敏感复发

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 余敏华;金明珠;狄文;

DOI: 10.13283/j.cnki.xdfckjz.2021.06.017

参考文献(References)：

• [1] 中华人民共和国国家卫生健康委员会，卵巢癌诊疗规范(2018年版)
• [2] 中华医学会妇科肿瘤学分会.卵巢癌PARP抑制剂临床应用指南[J].现代妇产科进展，2020,29(5):321-327
• [3] Giornelli GH.Management of relapsed ovarian cancer:a review[J].Springerplus,2016,5(1):1197
• [4] Ashworth A,Lord CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors?[J].Nat Rev Clin Oncol,2018,15(9):564-576
• [5] Lord CJ,Ashworth A.PARP inhibitors:Synthetic lethality in the clinic[J].Science,2017,355(6330):1152-1158
• [6] Sandhu S,Schelman W,Wilding G,et al.The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer:a phase 1 dose-escalation trial[J].Lancet Oncol,2013,149(9):882-892
• [7] Wu L,Zhu J,Yin R,et al.Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation:SOLO1 China cohort[J].Gynecol Oncol,2021,160(1):175-181
• [8] Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].N Engl J Med,2016,375(22):2154-2164
• [9] Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med,2012,366(15):1382-1392
• [10] Pujade-Lauraine E,Ledermann JA,Selle F,et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21):a double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18(9):1274-1284
• [11] Coleman RL,Oza AM,Lorusso D,et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10106):1949-1961
• [12] Ray-Coquard I,Pautier P,Pignata S,et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer[J].N Engl J Med,2019,381(25):2416-2428
• [13] Coleman R,Fleming G,Brady M,et al.Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer[J].N Engl J Med,2019,381(25):2403-2415
• [14] Wang D,Zou L,Jin Q,et al.Human carboxylesterases:a comprehensive review[J].Acta Pharm Sin B,2018,8(5):699-712
• [15] Moore KN,Secord AA,Geller MA,et al.Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA):a multicentre,open-label,single-arm,phase 2 trial[J].Lancet Oncol,2019,20(5):636-648
• [16] Domchek SM,Aghajanian C,Shapira-Frommer R,et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J].Gynecol Oncol,2016,140(2):199-203
• [17] Penson R.Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts):Phase III SOLO3 trial[C].ASCO Annual Meeting,2019
• [18] Vanderstichele A,Van Nieuwenhuysen E,Han S,et al.Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer[J].J Clin Oncol,2019,37:5507
• [19] Kristeleit R,Shapiro GI,Burris HA,et al.A Phase I-II Study of the Oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors[J].Clin Cancer Res,2017,23(15):4095-4106
• [20] Swisher EM,Lin KK,Oza AM,et al.Rucaparib in relapsed,platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1):an international,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2017,18(1):75-87
• [21] Liu J,Barry W,Birrer M,et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:a randomised phase 2 study[J].Lancet Oncol,2014,15(11):1207-1214
• [22] Liu J,Barry W,Birrer M,et al.Overall survival and updated progression-free survival outcomes in a randomized phase Ⅱ study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J].Ann Oncol,2019,30(4):551-557
• [23] Mirza M,Avall L,Birrer M,et al.Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer(NSGO-AVANOVA2/ENGOT-ov24):a randomised,phase 2,superiority trial[J].Lancet Oncol,2019,20(10):1409-1419
• [24] Falchook G,Coleman Rl,Roszak A,et al.Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer:a randomized clinical trial[J].JAMA Oncol,2019,5(1):e183773
• [25] Konstantinopoulos P,Waggoner S,Vidal G,et al.Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum resistant ovarian carcinoma[J].JAMA Oncol,2019,5(8):1141-1149